Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | BET and FLT3 inhibitor combinations for FLT3-ITD AML

Mark Levis • 27 May 2021
EHA 2021
Acute Myeloid Leukemia Leukemia

Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses using a combination therapy of bromodomain and extraterminal protein (BET) inhibitors and FMS-like tyrosine kinase 3 (FLT3) inhibitors to treat patients with FLT3 internal tandem duplication (FLT3-ITD)-mutated acute myeloid leukemia (AML). Dr Levis discusses how the difficulties of killing leukemic cells in the bone marrow microenvironment led to the development of this combination therapy in vitro. Promising in vitro results support the proposal that this combination therapy may be effective in clinical trials. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Mark Levis

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:03
Personalizing AML treatment by targeting MRD mutations
Mark Levis • 10 Dec 2023
2:00
FLT3-ITD-specific MRD predicts outcomes of chemotherapy in AML
Mark Levis • 10 Dec 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals